LENZ Therapeutics is a fully legitimate, publicly traded biopharmaceutical company listed on the Nasdaq global market under the ticker symbol LENZ. Backed by institutional investors, seasoned pharmaceutical executives, and rigorous clinical trial data that successfully secured official U.S. Food and Drug Administration (FDA) approval for its flagship therapeutic eye drop, the company operates within fully regulated commercial and securities frameworks.